Delayed cutaneous wound healing in Fam129b/Minerva-deficient mice.
Oishi H, Itoh S, Matsumoto K, Ishitobi H, Suzuki R, Ema M, Kojima T, Uchida K, Kato M, Miyata T and Takahashi S.
J Biochem. 2012; 152(6): 549-555.

Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions.
Itoh F, Itoh S, Adachi T, Ichikawa K, Matsumura Y, Takagi T, Festing M, Watanabe T, Weinstein M, Karlsson S and Kato M.
Blood. 2012; 119(22): 5320-5328.


Interference of E2-2-mediated effect in endothelial cells by FAM96B through its limited expression of E2-2.
Yang W, Itoh F, Ohya H, Kishimoto F, Tanaka A, Nakano N, Itoh S and Kato M.
Cancer Sci.2011; 102(10): 1808-1814.

Establishment of a novel monoclonal antibody SMab-1 specific for IDHI-R132S mutation.
Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C and Kato Y.
Biochem Biophys Res Commun. 2011; 406(4): 608-613.

Overexpression of the Transcription Factor Yin-Yang-1 Suppresses Differentiation of HaCaT Cells in Three-Dimensional Cell Culture.
Taguchi S, Kawachi Y, Ishitsuka Y, Fujisawa Y, Furuta J, Nakamura Y, Xu X, Ikebe D, Kato M and Otsuka F.
J Invest Dermatol. 2011; 131(1): 37-45.

病理診断に役立つ分子生物学 TGF-β 解説編, TGF-β 診断編
渡邊幸秀, 加藤光保
病理と臨床 臨時増刊号 2011; 29: 432-439.


Tissue- and Development-Dependent Expression of the Small GTPase Arf6 in Mice.
Akiyama M, Zhou M, Sugimoto R, Hongu T, Furuya M, Funakoshi Y, Kato M, Hasegawa H and Kanaho Y.
Dev Dynam. 2010; 239(12): 3416-3435.

Requirement of TCF7L2 for TGF-β-dependent transcriptional activation of the TMEPAI gene.
Nakano N, Itoh S, Watanabe Y, Maeyama K, Itoh F and Kato M.
J Biol chem. 2010; 285(49): 38023-38033.

TGF-β Signaling in Gingival Fibroblast-Epithelial Interaction.
Ohshima M, Yamaguchi Y, Matsumoto N, Micke P, Takenouchi Y, Nishida T, Kato M, Komiyama K, Abiko Y, Ito K, Otsuka K and Kappert K.
J Dent Res. 2010; 89(11): 1315-1321.

Inhibition of endothelial cell activation by bHLH protein E2-2 and its impairment of angiogenesis.
Tanaka A, Itoh F, Nishiyama K, Takezawa T, Kurihara H, Itoh S and Kato M.
Blood. 2010; 115(20): 4138-4147.

Trichostatin A-Induced TGF-β Type II Recepter Expression in Retinoblastoma Cell Lines.
Kashiwagi Y, Horie K, Kanno C, Inomata M, Imamura T, Kato M, Yamamoto T and Yamashita H.
IOVS. 2010; 51(2); 679-685.

Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes.
Sonkoly E, Wei T, Pavez L, Suzuki H, Kato M, Torma H, Stahle M and Pivarcsi A.
J Invest Dermatol. 2010; 130(1): 124-134.

TMEPAI , a Transmembrane TGF-β-Inducible Protein, Sequesters Smad Proteins from Active Participation in TGF-β Signaling.
Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, Satoh K, Wiercinska E, Yang W, Shi L, Tanaka A, Nakano N, Mommaas AM, Shibuya H, ten Dijke P and Kato M.
Mol Cell. 2010; 37(1): 123-134.


Poor Vessel Formation in Embryos from Knock-in Mice Expressing ALK5 with L45 Loop Mutation Defective in Smad Activation.
Itoh F, Itoh S,Carvalho RLC, Adachi T, Ema M, Goumans MJ, Larsson J, Karlsson S, Takahashi S, Mummery CL, ten Dijke P and Kato M.
Lab Invest. 2009; 89(7): 800-810.

TAL1/SCL relieves the E2-2-mediated repression of VEGFR2 promoter activity.
Tanaka A, Itoh F, Itoh S and Kato M.
J Biochem. 2009; 145(2): 129-135.


Roles of mono-ubiquitinated Smad4 in the formation of Smad transcriptional complexes.
Wang B, Suzuki H and Kato M.
Biochem Biophys Res Commun. 2008; 376(2): 288-292.

Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma.
Suzuki H, Kato Y, Kaneko MK, Okita Y, Narimatsu H and Kato M.
FEBS Lett. 2008; 582(2): 341-345.

Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc min/+ mice.
Shi L, Itoh F, Itoh S, Takahashi S, Yamamoto M and Kato M.
Oncogene. 2008; 27(23): 3265-3273.


Nagative regulation of TGF-beta receptor/Smad signal transduction.
Itoh S, ten Dijke P.
Curr Opin Cell Biol. 2007; 19(2): 176-184.

Suppression of MafA-dependent transcription by transforming growth factor-beta signaling.
Matsumura H, Kudo T, Harada A, Esaki R, Suzuki H, Kato M and Takahashi S.
Biochem Biophys Res Commun.2007; 364(1): 151-156.

Compensatory signalling induced in the yolk sac vasculature by deletion of TGF receptors in mice.
Carvalho RL, Itoh F, Goumans MJ, Lebrin F, Kato M, Takahashi S, Ema M, Itoh S, van Rooijen M, Bertolino P, ten Dijke P and Mummery CL.
J Cell Sci. 2007; 120(Pt 24): 4269-4277.

Suppression of keratinocyte stratification by a dominant negative JunB mutant without blocking cell proliferation.
Ikebe D, Wang B, Suzuki H and Kato M.
Genes Cells.2007; 12(2): 197-207.

細胞. 2007; 39(8): 322-326.


Methylation of Smad6 by Protein Arginine N-Methyltransferase 1.
Inamitsu M, Itoh S, Hellman U, ten Dijke P and Kato M.
FEBS lett. 2006; 580(28-29): 6603-6611.

ELAC2, A Putative Prostate Cancer Susceptibility Gene Product, Potentiates TGF-β/Smad-induced Growth Arrest of Prostate Cells.
Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F, Koike S, Dnielpour D, ten Dijke P and Kato M.
Oncogene. 2006; 25(41): 5591-5600.


Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells.
Suzuki H, Watabe T, Kato M, Miyazawa K and Miyazono K.
Blood. 2005; 105(6): 2372-2379.

Cell type-specific regulation of the TGF-β-responsive alpha2(I) collagen gene by CpG methylation.
Yamane K, Suzuki H, Ihn H, Kato M, Yoshikawa H and Tamaki K.
J Cell Physiol.2005; 202(3): 822-830.

予防医学事典. 朝倉書店, 2005; 358-359.


A Role for Id in the Regulation of TGF-β-induced epithelial-mesenchymal transdifferentiation.
Kondo M, Cubillo E, Tobiume K, Shirakihara T, Fukuda N, Suzuki H, Shimizu K, Takehara K, Cano A, Sitoh M and Miyazono K.
Cell Death Differ.2004; 11(10): 1092-1101.

Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells.
Sato S, Miyauchi M, Kato M, Kitajima S, Kitagawa S, Hiraoka M, Kudo Y, Ogawa I and Takata T.
Pathobiology. 2004; 71(4): 171-175.

c-Ski inhibits the TGF-β signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements.
Suzuki H, Yagi K, Kondo M, Kato M, Miyazono K and Miyazawa K.
Oncogene. 2004; 23(29): 5068-5076.

CREB Cooperates with BMP-stimulated Smad signaling to enhance transcription of the Smad6 promoter.
Ionescu AM, Drissi H, Schwarz EM, Kato M, Puzas JE, McCance DJ, Rosier RN, Zuscik MJ and O'Keefe RJ.
J Cell Physiol. 2004; 198(3): 428-440.

Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells.
Itoh F, Itoh S, Goumans MJ, Valdimardottir G, Iso T, Dotto GP, Hamamori Y, Kedes L, Kato M and ten Dijke P.
EMBO J. 2004; 23(3): 541-551.

Transforming growth factor-β signaling is differentially inhibited by Smad2D450E and Smad3D407E.
Kondo M, Suzuki H, Takehara K, Miyazono K and Kato M.
Cancer Sci.2004; 95(1): 12-17.

キーワードで理解する転写イラストマップ. 羊土社, 2004; 176-193.

サイトカイン・増殖因子用語ライブラリー. 羊土社, 2004.


Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells.
Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, Miyazono K, Rodan GA, Takeuchi Y and Fujita T.
J Bone Miner Res. 2003 May; 18(5): 827-835.

Activin receptor-like kinase(ALK)1 is an antagonisitic mediator of lateral TGF-β/ALK5 signaling.
Goumans M, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S and ten Dijke P.
Mol Cell. 2003 Oct; 12(4): 817-828

Synthetic triterpenoids enhance transforming growth factor β/Smad signaling.
Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW and Sporn MB.
Cancer Res. 2003 Mar 15; 63(6): 1371-1376

SARA and Hgs attenuate susceptibility to TGF-β1-mediated T cell suppression.
Kunzmann S, Wohlfahrt JG, Itoh S, Asao H, Komada M, Akdis CA, Blaser K and Schmidt-Weber CB.
FASEB J.2003 Feb;17(2): 194-202

Elucidation of Smad requirement in transforming growth factor-β type I receptor-induced responses.
Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH and ten Dijke P.
J Biol Chem.2003 Feb; 278(6): 3751-3761

Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor β-induced repression of c-myc.
Sasaki T, Suzuki H, Yagi K, Furuhashi M, Yao R, Susa S, Noda T, Arai Y, Miyazono K and Kato M.
Cancer Res. 2003 Feb 15; 63(4): 801-806.

トランスフォーミング増殖因子 βによる転写制御(PDF)
蛋白質 核酸 酵素. 2003 Dec; 48(16): 2247-2253


Compound disruption of Smad2 accelerates malignant progression of intestinal tumors in Apc knockout mice.
Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K and Kato M.
Cancer Res. 2002 Oct 15; 62(20): 5955-5961.

c-myc is a downstream target of the Smad pathway.
Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, Miyazono K and Kato M.
J Biol Chem. 2002 Jan 4; 277(1): 854-861.